BR0316206A - Uso inibidores de histona desacetilase para o tratamento de distúrbios e de doenças oculares neovasculares ou edematosos - Google Patents

Uso inibidores de histona desacetilase para o tratamento de distúrbios e de doenças oculares neovasculares ou edematosos

Info

Publication number
BR0316206A
BR0316206A BR0316206-0A BR0316206A BR0316206A BR 0316206 A BR0316206 A BR 0316206A BR 0316206 A BR0316206 A BR 0316206A BR 0316206 A BR0316206 A BR 0316206A
Authority
BR
Brazil
Prior art keywords
edematous
neovascular
treatment
histone deacetylase
deacetylase inhibitors
Prior art date
Application number
BR0316206-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Peter G Klimko
David P Bingaman
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of BR0316206A publication Critical patent/BR0316206A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR0316206-0A 2002-11-12 2003-10-30 Uso inibidores de histona desacetilase para o tratamento de distúrbios e de doenças oculares neovasculares ou edematosos BR0316206A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42557402P 2002-11-12 2002-11-12
PCT/US2003/034617 WO2004043352A2 (en) 2002-11-12 2003-10-30 Histone deacetylase inhibitors for the treatment of ocular neovascular or edematous disorders and diseases

Publications (1)

Publication Number Publication Date
BR0316206A true BR0316206A (pt) 2005-09-27

Family

ID=32313018

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0316206-0A BR0316206A (pt) 2002-11-12 2003-10-30 Uso inibidores de histona desacetilase para o tratamento de distúrbios e de doenças oculares neovasculares ou edematosos

Country Status (12)

Country Link
US (3) US20060074100A1 (https=)
EP (1) EP1560583A4 (https=)
JP (1) JP2006512318A (https=)
KR (1) KR20050086526A (https=)
CN (1) CN1711087A (https=)
AU (1) AU2003287349B2 (https=)
BR (1) BR0316206A (https=)
CA (1) CA2504460A1 (https=)
MX (1) MXPA05004485A (https=)
RU (1) RU2352337C2 (https=)
WO (1) WO2004043352A2 (https=)
ZA (1) ZA200503237B (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
JP2006512318A (ja) * 2002-11-12 2006-04-13 アルコン，インコーポレイテッド 眼の血管新生もしくは水腫状の疾患および障害を処置するためのヒストンデアセチラーゼインヒビター
US7381825B2 (en) 2003-03-17 2008-06-03 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2004089293A2 (en) * 2003-04-01 2004-10-21 Memorial Sloan-Kettering Cancer Center Hydroxamic acid compounds and methods of use thereof
US20050197336A1 (en) * 2004-03-08 2005-09-08 Miikana Therapeutics Corporation Inhibitors of histone deacetylase
US7345043B2 (en) * 2004-04-01 2008-03-18 Miikana Therapeutics Inhibitors of histone deacetylase
MX2007001550A (es) * 2004-08-09 2007-04-10 Astellas Pharma Inc Compuestos de hidroxiamida que tienen actividad como inhibidores de histona desacetilasa (hdac).
EP1824831A2 (en) 2004-12-16 2007-08-29 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7772245B2 (en) 2005-02-14 2010-08-10 Miikana Therapeutics, Inc. Inhibitors of histone deacetylase
AU2006243000B2 (en) * 2005-05-05 2011-05-26 Macrophage Pharma Limited Alpha aminoacid ester-drug conjugates hydrolysable by carboxylesterase
GB0509225D0 (en) * 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Inhibitors of enzymatic activity
EP1896436A2 (en) 2005-05-11 2008-03-12 Takeda San Diego, Inc. Histone deacetylase inhibitors
EA200800321A1 (ru) 2005-07-14 2008-06-30 Такеда Сан Диего, Инк. Ингибиторы гистондеацетилазы
US20100004156A1 (en) * 2005-07-27 2010-01-07 Shalesh Kaushal Small Compounds That Correct Protein Misfolding and Uses Thereof
CA2641579A1 (en) * 2006-02-07 2007-08-16 Astellas Pharma Inc. N-hydroxyacrylamide compounds
WO2007113644A2 (en) * 2006-04-05 2007-10-11 Orchid Research Laboratories Limited New hdac inhibitors
WO2008053131A1 (en) * 2006-10-30 2008-05-08 Chroma Therapeutics Ltd. Hydroxamates as inhibitors of histone deacetylase
MX2009006129A (es) * 2006-12-15 2009-06-18 Astellas Pharma Inc Compuestos de n-hidroxiacrilamida.
CN101239929B (zh) * 2007-02-09 2013-04-17 中国科学院上海药物研究所 曲古抑菌素a衍生物及其制备方法和用途
JP2008266321A (ja) * 2007-03-28 2008-11-06 Santen Pharmaceut Co Ltd フェニレンジアミン誘導体を有効成分とする眼圧下降剤
JP2019531296A (ja) * 2016-09-29 2019-10-31 彦臣生技藥品股▲ふん▼有限公司ＮａｔｕｒｅＷｉｓｅ Ｂｉｏｔｅｃｈ＆ Ｍｅｄｉｃａｌｓ Ｃｏｒｐｏｒａｔｉｏｎ 眼疾患の処置方法
WO2019089573A1 (en) * 2017-10-30 2019-05-09 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Treatment of ocular conditions utilizing a histone/protein deacetylase inhibitor
KR102236356B1 (ko) 2017-11-24 2021-04-05 주식회사 종근당 루푸스의 예방 또는 치료를 위한 조성물
KR20190099952A (ko) * 2018-02-20 2019-08-28 주식회사 종근당 포도막염의 예방 또는 치료를 위한 조성물
WO2019246509A1 (en) * 2018-06-22 2019-12-26 Mohan Rajiv R Methods and compositions for promoting wound healing with decreased scar formation after glaucoma filtration surgery
WO2020102599A1 (en) * 2018-11-14 2020-05-22 Vanderbilt University Treating intraocular retinoblastoma with inhibitors of histone modification
RU2769320C1 (ru) * 2020-12-28 2022-03-30 Федеральное государственное бюджетное учреждение науки Институт проблем химической физики Российской академии наук (ИПХФ РАН) Способ получения производных N-гидроксибутанамида

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4975537A (en) * 1985-10-23 1990-12-04 The Upjohn Company Δ9(11) -angiostatic steroids
US4771042A (en) * 1985-11-25 1988-09-13 The Upjohn Company Inhibition of angiogenesis involving the coadministration of steroids with heparin or heparin fragments
US5629327A (en) * 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
GB9804504D0 (en) * 1998-03-03 1998-04-29 Leo Pharm Prod Ltd Matrix metalloproteinase inhibitors
AUPP505798A0 (en) * 1998-08-04 1998-08-27 Fujisawa Pharmaceutical Co., Ltd. Novel compound fr225497 substance
KR20010080142A (ko) * 1998-10-13 2001-08-22 후지야마 아키라 사이클릭 테트라펩티드 화합물 및 이의 용도
US6953783B1 (en) * 1998-10-19 2005-10-11 Methylgene, Inc. Modulation of gene expression by combination therapy
WO2000059865A1 (en) * 1999-04-06 2000-10-12 Ono Pharmaceutical Co., Ltd. 4-aminobutanoic acid derivatives and drugs containing these derivatives as the active ingredient
NZ517613A (en) * 1999-09-08 2004-01-30 Sloan Kettering Inst Cancer Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof
US6544957B2 (en) * 2000-01-04 2003-04-08 The Johns Hopkins University Methods and reagents for facilitating transcription
AR030345A1 (es) * 2000-08-14 2003-08-20 Alcon Inc Metodo de tratamiento de desordenes relacionados con angiogenesis
GB0023983D0 (en) * 2000-09-29 2000-11-15 Prolifix Ltd Therapeutic compounds
RU2177801C1 (ru) * 2001-01-25 2002-01-10 Санкт-Петербургская Общественная Организация "Санкт-Петербургский Институт Биорегуляции И Геронтологии Сзо Рамн" Средство, ингибирующее ангиогенез при заболеваниях органа зрения
JPWO2002074298A1 (ja) * 2001-03-21 2004-07-08 小野薬品工業株式会社 Ｉｌ−６産生阻害剤
US6905669B2 (en) * 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
AU2002340253C1 (en) * 2001-10-16 2011-03-31 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases and cancer of the brain
US7154002B1 (en) * 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
RU2324483C2 (ru) * 2002-11-12 2008-05-20 Алькон, Инк. Ингибиторы гистондеацетилазы для лечения дегенеративных заболеваний глаз
JP2006512318A (ja) * 2002-11-12 2006-04-13 アルコン，インコーポレイテッド 眼の血管新生もしくは水腫状の疾患および障害を処置するためのヒストンデアセチラーゼインヒビター
US20080004311A1 (en) * 2002-11-12 2008-01-03 Alcon, Inc. Histone deacetylase inhibitors for treating degenerative diseases of the eye

Also Published As

Publication number Publication date
WO2004043352A8 (en) 2005-06-30
JP2006512318A (ja) 2006-04-13
US20100048608A1 (en) 2010-02-25
AU2003287349A1 (en) 2004-06-03
AU2003287349B2 (en) 2009-04-23
US20060074100A1 (en) 2006-04-06
RU2352337C2 (ru) 2009-04-20
WO2004043352A3 (en) 2004-07-15
MXPA05004485A (es) 2005-11-23
EP1560583A2 (en) 2005-08-10
CN1711087A (zh) 2005-12-21
ZA200503237B (en) 2006-06-28
RU2005118107A (ru) 2006-01-20
WO2004043352A2 (en) 2004-05-27
US20040092558A1 (en) 2004-05-13
CA2504460A1 (en) 2004-05-27
KR20050086526A (ko) 2005-08-30
EP1560583A4 (en) 2010-09-22

Similar Documents

Publication Publication Date Title
BR0316206A (pt) Uso inibidores de histona desacetilase para o tratamento de distúrbios e de doenças oculares neovasculares ou edematosos
ATE443043T1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
BR0316163A (pt) Inibidores de histona desacetilase para tratamento de doenças degenerativas do olho
BR0316350A (pt) Diaminotriazóis úteis como inibidores de proteìna cinases
ATE414519T1 (de) Kombination aus einem nmda-antagonist und acetylcholinesterase-hemmern zur behandlung der alzheimer-krankheit
BR9917038A (pt) Composto, composição farmacêutica, método de modulação da atividade receptora de quimocinas, método de tratamento ou prevenção de doenças inflamatórias, método de tratamento ou prevenção de asma e método de tratamento ou prevenção de disfunções inflamatórias
BRPI0407993A (pt) inibidores de p38 e métodos para uso dos mesmos
EA200501017A1 (ru) Астма и модуляторы аллергических воспалений
BR0312421A (pt) Uso de inibidores de cept e opcionalmente inibidores hmg coa redutase e/ou agentes anti-hipertensivos
BRPI0514395A (pt) uso terapêutico de inibidores de rtp801
ATE353319T1 (de) Acetylenderivate als inhibitoren von histondeacetylase
BRPI0407922A (pt) derivados de isoquinolina e métodos de uso destes
ATE416761T1 (de) Prävention und behandlung von durch entzündung ausgelöstem und/oder immunvermitteltem knochenschwund
DK1465626T3 (da) Farmaceutiske præparater (kit) der omfatter dihydropyridinonforbindelser og et immunregulatorisk (eller et antiinflammatorisk) middel samt anvendelser deraf
WO2002046129A3 (en) Inhibitors of histone deacetylase
BR0308663A (pt) Uso de inibidores de il-18 para o tratamento e/ou prevenção de doenças vasculares periféricas
NO20055216D0 (no) Nye hydroksamater som terapeutiske midler
DE69926919D1 (de) N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren
BR0209812A (pt) Uso de osteopontina para o tratamento e/ou a prevenção de doenças neurológicas
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
EA200401183A1 (ru) Применение ингибиторов il-18 в качестве диагностического маркера
BR0214672A (pt) Inibidores de fosfolipase citosólica a2
BRPI0411864A (pt) combinação de inibidores de src quinase e agentes quimioterápicos para o tratamento de doenças proliferativas
NZ334605A (en) C-terminal modified (n-substituted)-2-indolyl dipeptides as inhibitors of the ice/ced-3 family of cysteine proteases and for treatments of inflammatory, autoimmune, neurodegenerative disorders and in the prevention of ischemic injury
DE60121986D1 (de) Triptpolidanaloge zur verendung in der behandlung von autoimmunbedingten und entzündlichen erkrankungen

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]